EvaluatePharma Orphan Drug Report 2017

The steady and inexorable growth of the orphan drug market remains one of the prominent themes in the fourth edition of the EvaluatePharma Orphan Drug Report 2017.

What has changed in the last 12 months according to the report is the increased scrutiny of the price of these lifesaving products.

Key Highlights:

  • Worldwide orphan drug sales forecast to total $209bn (CAGR 2017 to 2022:+11.1%); approximately double overall prescription market growth

  • Orphan drugs set to be 21.4% of worldwide prescription sales by 2022 (excluding generics)

  • Median cost per patient differential 5.5 times higher for orphan drugs compared to non-orphan

 

Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry.

 

Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry.

Download Report